Divaza Lozenges, # 100

Combined preparation:

Antibodies to brain-specific protein S-100 have antioxidant, antihypoxant, neuroprotective, anxiolytic effects.

Modify the functional activity of the S-100 protein, which carries out

in the brain, the conjugation of information and metabolic processes.

They have a membranotropic effect, causing a decrease in amplitude and

suppression of action potential generation

modulate synaptic plasticity in the limbic structures of the brain, hippocampus, reticular formation

enhance the inhibitory effects of GABA in the central nervous system.

Exhibit sigma 1 receptor agonist properties in vitro.

They inhibit lipid peroxidation processes.

Have a normalizing effect on the integrative activity of the brain,

which is manifested by a wide range of balanced psychopharmacological effects: antidepressant, anxiolytic, neuroprotective, antiasthenic, antiamnesic.

Antibodies to endothelial NO synthase increase the activity of the enzyme endothelial NO synthase, restore endothelial production of nitric oxide (NO), eliminate endothelial dysfunction, have an endothelioprotective effect, and affect NO-dependent vasodilation.

The stimulating effect of Divaza on reparative processes in the focus of ischemic brain damage has been experimentally shown.

The combined use of the components of the drug is accompanied by an increase in the neuroprotective activity of antibodies to the S-100 protein, an increase in the vegetative-stabilizing effect, the normalization of the vegetative status, the synergistic effect of both components on neuronal plasticity, and, as a result, an increase in the brain's resistance to toxic effects

improves integrative activity and restores interhemispheric connections of the brain, helps to eliminate cognitive impairments, stimulates reparative processes and accelerates the restoration of central nervous system functions, increases mental performance, restores learning and memory processes, normalizes somatovegetative manifestations, and increases cerebral blood flow.

Divaza, as well as its constituent components, does not have a sedative and muscle relaxant effect, does not cause addiction and addiction.

Name ENG

DIVAZA

Clinical and pharmacological group

Antihypoxant, antioxidant, nootropic, angioprotective drug

ATX code

Antihypoxic, antioxidant, nootropic, angioprotective drug

< br> Other anxiolytics < br> Other psychostimulants and nootropic drugs < br> Other drugs for the treatment of dementia < br>

Dosage

6mg + 6mg

Structure

Table 1: - antibodies to brain-specific protein S-100 affinity purified * 0.006 g - antibodies to endothelial NO-synthase affinity purified * 0.006 g. Excipients: lactose monohydrate

MCC

magnesium stearate.

Indications

As part of complex therapy:

- restoration of the integrative activity of the brain in a wide range of organic disorders of the central nervous system, incl.

caused by neurodegenerative diseases, cerebrovascular (including ischemic) diseases, neuroinfections, traumatic brain injury.

Monotherapy:

- somatoform dysfunction of the autonomic nervous system.

Contraindications

Increased individual sensitivity to drug components.

Divaza is not recommended for use in patients under the age of 18 years due to insufficient data on efficacy and safety for this age.

Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Storage conditions and periods

In a dark place at a temperature not exceeding 25 degrees.

Expiration date: 3 years

INN / Active ingredient

Homeopathic composition

Specifications

Category

Nootropic drugs

,

Memory impairment

Scope of the drug

Neurology, psychiatry

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

one hundred

Scope of application

Neurology

,

Psychiatry

Minimum age from

18 years

Vacation conditions

Without recipe

Brand name

Materia Medica Holding

The amount of the dosage form in the primary package

20 pcs.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Nootropic agent

Anatomical and therapeutic characteristics

N06BX Other psychostimulants and nootropics

Dosage form

Lozenges

Packaging

Box

Expiration date in days

1095

The target audience

Adult

Package weight, g

45

Mode of application

:

Inside. < br> At one time - 1 table.

(keep in mouth until completely dissolved).

Take 1-2 tables.

3 times a day outside meals.

Depending on the severity of the condition, in the acute period, the frequency of admission can be increased up to 4-6 times a day. < br> With pronounced organic lesions of the central nervous system, the duration of the course therapy can reach 4-6 months.

Dosage (volume) of the substance in the preparation

:

antibodies to brain-specific protein S-100 affinity purified 0.006 g, antibodies to endothelial NO synthase affinity purified 0.006